Exclusive Summary

• The 40mg dosage holds US FDA ANDA approval, providing world-class cGMP endorsement to facilitate fast-track or waiver-based registrations for distributors in emerging markets.
• Offering a comprehensive portfolio of 40mg, 60mg, and 80mg fulfills diverse clinical needs ranging from standard acid suppression to critical care (e.g., 80mg bolus), creating a distinct competitive edge in hospital tender portfolios.
• Backed by China's mature API-to-finished-product integrated supply chain, the product boasts significant economies of scale and cost advantages, perfectly aligning with global healthcare cost-containment trends and ensuring lucrative margins for distributors.